Omega-3 in ASCENT, VITAL and REDUCE-IT Trials: What have We Learned?

Deepak L. Bhatt, MD, MPH
Brigham and Women’s Hospital
Boston, MA

Applying Cardiovascular Outcome Trial Data to T2DM Management

Darren K. McGuire, MD, MHSc
University of Texas Southwestern
Medical School
Dallas, TX

Measuring Cardiovascular Risk: Remnant Cholesterol vs. LDL Cholesterol

Samia Mora, MD, MHS
Brigham and Women’s Hospital
Boston, MA

Redefining the Standard of Care for CAD and PAD: Combining Antiplatelet Therapy with Low Dose Anticoagulation

Christopher B. Granger, MD
Duke Clinical Research Institute
Duke University
Durham, North Carolina

Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy: Past, Present and Future

Sanjiv J. Shah, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Coronary Microvascular Dysfunction: A Causal Mechanistic Pathway for HFpEF?

Marcelo Fernando Di Carli, MD
Brigham and Women’s Hospital
Boston, MA

State of the Art Management of HFpEF and Glimpses Into the Future.

Sanjiv J. Shah, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Eliminating Atrial Fibrillation: Is Catheter Ablation Superior to State-of-the-art Pharmacologic Therapy?

Gerald V. Naccarelli, MD
Penn State University
School of Medicine
Hershey, PA

Lipids, Liver and Cardiovascular Disease

Anne Tybjaerg Hansen, MD, DMSc
Rigshospitalet Copenhagen
University Hospital
Copenhagen, Denmark

Is It Time for Cardiology to Embrace Novel Therapeutic Options in Diabetes?

Steven P. Marso, MD, FACC
HCA Midwest Health
Kansas City, MO

Renal Denervation for Hypertension: Is it Back?

Michael Böhm, MD, PhD, FESC
Saarland University Medical Center
Homburg, Germany

Expanding Indications for Direct Oral Anticoagulants

Michael Ezekowitz, MBChB, DPhil, FACC
Thomas Jefferson University Hospital
Philadelphia, PA

New Approaches to Pulmonary Hypertension: Why Aren’t More Cardiologists Interested in PAH?

Mardi Gomberg-Maitland, MD, MSc, FACC
Inova Heart and Vascular Institute
Falls Church, VA

Prevention and Monitoring of Cardiac Dysfunction in Cancer Patients

Anju Nohria, MD, MSc
Brigham and Women’s Hospital
Boston, MA

Immune Checkpoint-associated Myocarditis: A New Entity in Cardio-Oncology

Javid J. Moslehi, MD
Vanderbilt School of Medicine
Nashville, TN

Adipose-derived Cell-based Therapies for CVD: From Cells to Secretome

Keith March, MD, PhD, FACC
University of Florida College of Medicine
Gainesville, FL

ORBITA Redux / To Stent or Not: Yes, Revascularization is Still Standard of Care

Ajay J. Kirtane, MD, FACC
Columbia University Medical Center
New York, NY

Emerging Approaches to Dyslipidemia Management Beyond LDL-C

Eliot A. Brinton, MD, FAHA, FNLA
Utah Lipid Center
Salt Lake City, UT

How Big Data and Population Health Management are Changing CVD Treatment and Prevention

Robert M. Califf, MD, MACC
Duke University
School of Medicine
​Durham, NC

Nanotherapeutic Solutions for Peripheral Arterial Disease

John P. Cooke, MD, PhD, FACC
Houston Methodist Research Institute
Houston, TX

Recent Advances in Diagnostic Imaging for Peripheral Arterial Disease

Joao A. C. Lima, MD, FACC
Johns Hopkins School of Medicine
Baltimore, MD

Transcatheter Mitral Valve Replacement: Hope or Hype?

Howard C. Herrmann, MD, FACC
University of Pennsylvania
Philadelphia, PA

Will Incretin Therapy Change Obesity and Prediabetes Management?

Sanjay Rajagopalan, MD, FACC
Case Western Reserve University School of Medicine
Cleveland, OH

Time to Start Prescribing Diabetes Agents: A Cardiologists Call to Action

David H. Fitchett, MD, FACC
University of Toronto
Toronto, ON, Canada

Regression of Coronary Atherosclerosis: Current Evidence and Future Perspectives

Stephen J. Nicholls, MBBS, PhD, FACC
University of Adelaide
Adelaide, Australia

Therapeutic Targeting of LP(a), APOC-III, and ATP-Citrate Lyase for Cardiovascular Disease

Sotirios Tsimikas, MD, FACC
UC San Diego School of Medicine
La Joila, CA

Aspirin: How Important is Platelet Resistance?

Jawahar L. Mehta, MD, PhD, FACC
University of Arkansas for Medical Sciences
Little Rock, AR

Cardiorenal Disorders: Recent Advances, Novel Therapies

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

Using TAVR in Lower and Lower Risk Patients.

Ron Waksman, MD
Washington Hospital Center
Washington, DC

Lipids 2016: Update on the Metamorphosis Occurring in Lipid Therapy Today.

Robert P. Giugliano, MD
TIMI Study Group
Boston, MA  

Benefits and Limitations of Antiplatelet Therapy. How Can We Advance the Field?

Paul A. Gurbel, MD
Johns Hopkins University School of Medicine
Baltimore, MD 

Current and Future Perspectives in the Treatment of Pulmonary Hypertension.

Paul R. Forfia, MD
Temple University School of Medicine
Philadelphia, PA

Is it Time to Reappraise BP Targets to Further Reduce CVD Risk and Death?

William Cushman, MD, FACP
University of Tennessee College of Medicine
​Memphis, TN

Targeted Inhibition of Inflammation to Reduce Cardiovascular Event Rates: Lessons Learned From CANTOS

Paul M. Ridker, MD, FACC
Brigham and Women’s Hospital
​Boston, MA

LDL-C Lowering: Is Lowest Best?

Robert P. Giugliano, MD, FACC
Brigham and Women’s Hospital
​Boston, MA

Preventing Heart Failure and Providing CVD Protection in Patients with Diabetes

Darren K. McGuire, MD, MHSc, FACC
UT Southwestern Medical Center
​Dallas, TX

Gut Microbiota as a Target for Cardio-Renal Risk

W. H. Wilson Tang, MD, FACC
Cleveland Clinic
Cleveland, OH

What Have We Learned From Recent Trials for PAD and Where Are We Headed?

William R. Hiatt, MD
University of Colorado School of Medicine
Denver, CO 

HIV, Inflammation and Cardiovascular Disease

Priscilla Y. Hsue, MD, FACC
UCSF School of Medicine
San Francisco, CA

Utilizing Novel Therapies in Atherosclerosis: From Antibodies to Nanotechnology

Erik Stroes MD, PhD
Academic Medical Center
Amsterdam, Netherlands

Modifying CVD Risk by Managing Hyperglycemia: The Dawn of a New Era?

Jorge Plutzky, MD
Brigham and Women's Hospital
Boston, MA

Advancing the Cardiovascular Care of Our Cancer Patients: Where Are We Now?

Javid Moslehi, MD
Vanderbilt University
School of Medicine
Nashville, TN

Tailoring Oral Anticoagulation in Elderly Patients with Atrial Fibrilation

Christopher Granger, MD
Duke University
School of Medicine
Durham, NC

How We Should Manage HTN in Adults: The Importance of Diastolic Blood Pressure with Lower Systolic Targets

Deepak Bhatt, MD, MPH
Brigham and Women's Hospital 
Heart and Vascular Center
Boston, MA

Cardiac Care for Older Adults: Why is the Demography Important?

Nanette Wenger, MD
Emory University
School of Medicine
Atlanta, GA

Living with Heart Disease in Old Age: Shifting Priorites of Care for Older Cardiac Patients

Daniel Forman, MD
Professor, Department of Medicine
University of Pittsburgh

HFpEF in Older Adults: TTR Amyloid, Under Diagnosed and Treatable?

Mathew Maurer, MD
Columbia University
Medical Center
New York, NY

CKD: An Independent CV Risk Factor in the Elderly

George Bakris, MD
University of Chicago Medicine
Chicago, IL

No Automatic Prescribing in Those > 75 Years. Why Guideline Directed Clinician-Patient-Risk Discussion Crucial

Neil Stone, MD
Northwestern University
Feinburg School of Medicine
Chicago, IL

Integrating Big Data with Evidence Generation for Precision Medicine: Implications for Cardiovascular Disease.

Elliott M. Antman, MD, MACC
Immediate Past President AHA
Harvard Medical School
Boston, MA

Treating HTN Today: Insights from SPRINT and the New Clinical Practice Guidelines for Patients with CAD.

Clive Rosendorff, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Cardiovascular Outcomes with Medicines to Control Glycemia: Highlights from Recently Completed Trials.

Darren K. McGuire, MD, MHSc
UT Southwestern Medical Center
Dallas, TX

Where Are We With Systolic Heart Failure?

Ileana Pina, MD, MPH
Montefiore Medical Center
Bronx, NY

Are We Back to Lower is Better: Time to Revise the 2014 Guidelines?

Stephen D. Wiviott,  MD
Brigham and Women’s Hospital
Boston, MA 

New Directions in Antiplatelet Therapy

David A. Morrow, MD, MPH
Brigham and Women’s Hospital
Boston, MA

The Emerging Role of Gut Microbiota in CVD and Thrombosis.

Stanley L. Hazen, MD, PhD
Cleveland Clinic
Cleveland, OH

Reducing CV Risk with Glucose Lowering Drugs: Recent Breakthroughs.

Silvio E. Inzucchi, MD
Yale University School of Medicine
New Haven, CT

Eliminating Barriers That Prevent Optimal Stroke Prevention in Patients with Afib.

Christian T. Ruff, MD
Brigham and Women’s Hospital
Boston, MA

The Next Frontier in Heart Failure: Where Are We Going?

Scott D. Solomon, MD
Brigham and Women’s Hospital
Boston, MA 

Cardiorenal Disorders: Recent Advances, Novel Therapies.

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

Impacting Lipid Disorders Through Personalized Healthcare: What the Future Holds.

Daniel J. Rader, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Personalized Medicine in Patients with Coronary Artery Disease.

Jean-Claude Tardif, , MD
Montreal Heart Institute
Montreal, QC, Canada

The Future of Healthcare and the Role of the National Academy of Medicine.

Victor J. Dzau, MD
National Academy of Medicine
Washington, DC

Molecular Imaging in the Era of Personalized Medicine.

Mehran Sadeghi, MD
Yale University School of Medicine
New Haven, CT

NOACS for Valve Disease?

A. John Camm, MD
St. George’s University Hospital
London, UK

New Oral Interventions for Heart Failure.

Javed Butler,  MD, MPH
Stony Brooke University School of Medicine
Stony Brook, NY

Beyond Statins: The Coming Revolution in Lipid Therapy

Christie Ballantyne, MD
Baylor College of Medicine
Houston, TX

Cell Therapy: Where Are We Today and Where Are We Headed?

Eduardo Marban, MD, PhD
Cedars-Sinai Hospital
Los Angeles, CA

Bariatric Surgery for Obesity and Cardiometabolic Conditions: Time to Embrace?

Michael E. Farkouh, MD, MSc
University of Toronto
Toronto, ON, Canada 

Where Are We With Diastolic Heart Failure?

Christopher O’Connor, MD
Duke University Medical Center
Durham, NC

The Rapidly Evolving Field of TAVR

John G. Webb, MD
St. Paul’s Hospital
Vancouver, BC, Canada

Percutaneous MVR After Everest II: What the Future Holds

Ted E. Feldman, MD
NorthShore University HealthSystem
Evanston, IL

Heart Disease in Women: Have We Made Progress?

C. Noel Bairey Merz, MD
Cedars-Sinai Hospital

Managing Type 2 Diabetes: New and Future Developments in Treatment

Silvio E. Inzucchi, MD
Yale School of Medicine

New Developments in the Treatment of Heart Failure

John J. McMurray, MD
University of Glasgow

New Frontiers in Cardiac Biomarkers

Alan S. Maisel, MD
University of California San Diego

PCSK9 and Atherosclerosis: Will We Target Risk with Monoclonal Antibodies or Only LDL-C?

Michael J. Koren, MD
Jacksonville Ctr. For Clinical Research

HDL Dysfunction in Coronary Artery Disease: An Enigma or Dead?

Stephen J. Nicholls, MBBS, PhD
South Australian Health and Medical Research Institute

Emerging Therapies on the Horizon for Hypertriglyceridemia

Ira Goldberg, MD
NYU Langone Medical Center

Is Left Atrial Occlusion Really an Alternative to Lifelong Anticoagulation?

David R Holmes Jr. MD, Mayo Clinic, Rochester, MN

Turning White Fat to Brown: Foe to Friend or Not?

Jorge Plutzky MD, Brigham and Women's Hospital

Serelaxin: Breakthrough Therapy or Also-ran?

John R Teerlink MD, UCSF School of Medicine

A Novel Approach to Preventing Aortic Stenosis

Jean-Claude Tardif MD, Montreal Heart Institute

Future Pharmacological Options for Heart Failure

Christopher O'Connor MD, Duke University Medical Center

PCSK9 Inhibitors and the Unmet Need for LDL-C Reduction

Evan A Stein MD, PhD, University of Cincinnati

HRT: Help or Harm to the Heart?

Eliot A Brinton MD, University of Utah School of Medicine

High LP(a): Causal Role in Calcific Stenosis and Other CV Diseases

Sotirios Tsimikas MD, UC San Diego School of Medicine

Direct Inhibition of Inflammation: CANTOS, CIRT, and Beyond

Paul M Ridker MD, Brigham and Women's Hospital

New Approaches to Modifying Risk by Improved Glycemic Management

Deepak L Bhatt MD, MPH, Harvard Medical School

Aging, Longevity Genes and Atherosclerosis: The Key to Living to 100?

Thomas Luscher MD, University Hospital, Zurich, Switzerland

Novel Therapies for Pulmonary Hypertension: Where Are We Going?

Lewis J Rubin MD, UC San Diego School of Medicine

Oral Anticoagulants in Development

Robert P Giugliano MD, Brigham and Women's Hospital